NR3C2 and endothelial dysfunction: Currently, available steroidal MR antagonists (MRAs), i.e., spironolactone and eplerenone, have been proven clinically effective in patients with CKD (Bolignano et al., 2014) and demonstrated beneficial effects in different models of hypertension by ameliorating endothelial dysfunction (Quaschning et al., 2001; Sanz-Rosa et al., 2005) and reducing oxidative stress (Quaschning et al., 2001; Virdis et al., 2002; Sanz-Rosa et al., 2005).